Morningstar Gives AA- Credit Rating to Bristol-Myers Squibb (BMY)
Bristol-Myers Squibb (NYSE:BMY) has been given an “AA-” credit rating by Morningstar. The firm’s “AA-” rating indicates that the company is a very-low default risk. They also issued a negative credit outlook for the company and gave their stock a three star rating.
Several other analysts have also recently commented on the stock. Analysts at TheStreet reiterated a “buy” rating on shares of Bristol-Myers Squibb in a research note on Wednesday, August 27th. They noted that the move was a valuation call. Separately, analysts at Deutsche Bank initiated coverage on shares of Bristol-Myers Squibb in a research note on Wednesday, August 27th. They set a “hold” rating and a $52.00 price target on the stock. They noted that the move was a valuation call. Finally, analysts at Jefferies Group raised their price target on shares of Bristol-Myers Squibb from $43.50 to $45.00 in a research note on Monday, August 11th. They now have a “hold” rating on the stock. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and eight have given a buy rating to the stock. The company presently has an average rating of “Hold” and an average price target of $51.83.
Shares of Bristol-Myers Squibb (NYSE:BMY) opened at 50.53 on Thursday. Bristol-Myers Squibb has a one year low of $41.32 and a one year high of $57.49. The stock has a 50-day moving average of $49.7 and a 200-day moving average of $50.36. The company has a market cap of $83.774 billion and a price-to-earnings ratio of 31.42.
Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Thursday, July 24th. The company reported $0.48 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.44 by $0.04. The company had revenue of $3.89 billion for the quarter, compared to the consensus estimate of $3.85 billion. During the same quarter last year, the company posted $0.44 earnings per share. Bristol-Myers Squibb’s revenue was down 3.9% compared to the same quarter last year. Analysts expect that Bristol-Myers Squibb will post $1.81 EPS for the current fiscal year.
Bristol-Myers Squibb Company (NYSE:BMY) is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products on a global basis.
To view more credit ratings from Morningstar, visit www.morningstar.com.